This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

Professionals 221 Users Online

miRNA Sequencing and Assay Market

Market Study on miRNA Sequencing: employment of newer approaches to extract the sequencing of miRNA to propel the market growth

Global miRNA Sequencing and Assay Market Technology - Sequencing by Synthesis | Sequencing by Oligonucleotide Ligation and Detection | Nanopore Seq. | Sanger Seq. and Single Molecule Real-time Seq.

miRNA Sequencing and Assay Market Outlook (2022-2032)

The newly released miRNA Sequencing and Assay Market analysis report by Persistence Market Research shows that global sales of the miRNA Sequencing and Assay Market in 2021 was held at US$ 227.7 Mn. With 18.1%, the projected market growth during 2022 - 2032 is expected to be significantly higher than the historical growth. Sequencing by Synthesis is expected to be the highest revenue-generating technology category, projected to register an opportunity of 20.8% CAGR 2022 – 2032.

Attributes

Details

Global miRNA Sequencing and Assay Market Size (2022)

US$ 267.7 Mn

Global miRNA Sequencing and Assay Market Size (2032)

US$ 1.4 Bn

Global miRNA Sequencing and Assay Market CAGR (2022-2032)

18.1%

U.S. miRNA Sequencing and Assay Market Size (2022)

US$ 109 Mn

Key Companies Covered

  • Thermo Fisher Scientific
  • Illumina
  • QIAGEN
  • PerkinElmer
  • Abcam plc
  • New England Biolabs
  • Takara Bio Inc.
  • Lexogen GmbH
  • Norgen Biotek Corp
  • Maravai LifeSciences
  • HTG Molecular Diagnostics
  • Meridian Bioscience, Inc.
  • System Biosciences, LLC
Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Revenue of miRNA Sequencing and Assay Market from 2017 to 2021 Compared to Demand Outlook for 2022 to 2032

As per the miRNA Sequencing and Assay Market research by Persistence Market Research, market research, and competitive intelligence provider, historically, from 2017 to 2021, market value of the miRNA Sequencing and Assay Market increased at around 16.2% CAGR.

Small RNA sequence analysis aids in the discovery of new miRNAs as well as other small RNAs, as well as the assessment of their differential expression in a sample. The approach is appropriate for analyzing microRNAs without previous intermediate structures or sequence information, as well as single-base resolution characterization of variants such as isomiRs. Furthermore, as the use of miRNA sequencing analysis grows, leading firms in the industry have made considerable expenditures.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

What Factors are Propelling miRNA Sequencing and Assay Demand?

The market is predicted to rise due to factors such as an increase in the frequency of infectious and communicable illnesses, technological advancements, and the employment of newer approaches to extract the sequencing of miRNA. The growing interest in miRNA biomarker identification might enhance the miRNA sequencing and testing business. Furthermore, market growth is due to factors such as an increase in the frequency of neurological illnesses and a rising demand for personalized treatments.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Region-wise Analysis

Which Region is projected to Offer the Largest Opportunity for the miRNA Sequencing and Assay Market?

North America is expected to account for the largest market at over 4% throughout the forecasted period. This is due to the presence of prominent firms in the region, including Illumina Inc., PerkinElmer, Inc., and Thermo Fisher Scientific among others. The key firms increased R&D expenditure in the United States to produce novel solutions. Illumina, Inc., for example, spent US$ 682 million on R&D in 2020 to create new sequence analysis technologies and enhance existing technology.

Due to the existence of organizations that are taking steps to teach researchers in this area, the market in the Asia Pacific is predicted to develop at the fastest rate throughout the forecast period. For example, APBioNet is an Asia Pacific informatics network that tracks the development of bioinformatics infrastructure, facilitates data and information sharing, and hosts training programs, seminars, and conferences.

Prerna Shiv

Prerna Shiv
Client Partner

Let's Connect

Conect me to identify wining opportunities

Ask An Expert
I'm Available

Country-wise Analysis

U.S. miRNA Sequencing and Assay Market Analysis

The United States is expected to have the highest market share of US$ 556.3 Mn by the end of 2032. miRNA sequencing & assay market in this country is developing due to factors such as increased investments in sequencing development, growing research in the disciplines of Genomics and RNA biology, and a rising need for cost-effective, high-throughput approaches for miRNA analysis.

U.K. miRNA Sequencing and Assay Market Analysis

The miRNA Sequencing and Assay Market in the U.K. is expected to reach a valuation of US$ 58.3 Mn in 2032, growing from US$ 8.8 Mn in 2021. During the forecast period, the market is expected to gross an absolute dollar opportunity of US$ 48 Mn.

Japan miRNA Sequencing and Assay Market Analysis

In Japan, the miRNA Sequencing and Assay Market is expected to reach a valuation of US$ 62 Mn, rising from US$ 7.2 Mn in 2021. With a CAGR of 22%, the market in the country is projected to garner an absolute dollar opportunity of US$ 53 Mn during 2022 – 2032.

South Korea miRNA Sequencing and Assay Market Analysis

The miRNA Sequencing and Assay Market in South Korea is expected to reach US$ 24.3 Mn, rising from US$ 4.2 Mn in 2021. Growing at a CAGR of 17.1%, the market is projected to gross US$ 19 Mn absolute dollar opportunity during 2022 – 2032.

Category-wise Insights

Which miRNA Sequencing and Assay Market is projected to Witness the Fastest Growth among the Component Types?

The product segment is forecasted to grow at the highest CAGR during 2022-2032. Illumina Inc., for example, provides a comprehensive suite of library preparation, sequence devices, accessories, consumables, software, and analytics for miRNA sequence analysis. Throughout the projected period, ongoing research to produce new products is anticipated to enhance sector market share.

Cold Spring Harbor Laboratory created BrumiR, an algorithm capable of discovering miRNAs directly and solely from sRNA-seq data. BrumiR was tested using datasets from animal and plant species, as well as actual and simulated sRNA-seq investigations. The results show that BrumiR has the greatest recollection for miRNA discovery while also being more efficient and more quickly than the current state-of-the-art methods.

Which miRNA Sequencing and Assay Market is projected to Witness the Fastest Growth among the Technology Type?

The sequencing by Synthesis (SBS) technology segment is forecasted to grow at the highest CAGR of 20.8% during 2022-2032. The continuous study and research in miRNA sequencing & assay by synthesizing is responsible for a substantial portion of the sector. Scientists from Germany, The United States, and China analyzed the conventional SBS and the approaches utilized for it in a January 2021 study. SBS retrieved more annotated miRNAs and created more new miRNAs, according to the findings.

SBS technology is also frequently used to analyze and investigate a variety of malignancies, as well as to develop tailored medicines. During the projected period, this is likely to account for a significant portion of the segment. SOLiD technology is noted for its accuracy, especially when such coverage is greater than 30x. As a result, it is widely employed in genetic recombination, transcriptome sequencing, and focused resequencing to detect changes. Currently, existing systems have 99.99% accuracy and a data source of 30 G for each run.

What is the impact of Covid-19 on the miRNA Sequencing and Assay Market?

During the Covid-19 outbreak, the researchers found that SARS-CoV-2 RNA sequences interacted with human MicroRNAs for developing a vaccine. MicroRNAs (miRNA) are a new and significant component of the virus-host cell interaction. Although it has been hypothesized that host miRNAs have an influence on SARS-CoV-2 infection. By crossing two luciferase-based reporter plasmids containing virus target sequences or their reversed sequences into the lungs A549 cell line, their contact with virus sequences was experimentally confirmed. The reporter plasmids reduced luciferase activity in five of the eight possible binding sites after transfection, indicating that they are sensitive to endogenously produced miRNAs.

Competitive Analysis

Some of the key companies operating in the miRNA Sequencing and Assay Market are Thermo Fisher Scientific, Illumina, QIAGEN, PerkinElmer, Abcam plc, New England Biolabs, Takara Bio Inc., Lexogen GmbH, Norgen Biotek Corp, Maravai LifeSciences, HTG Molecular Diagnostics, Meridian Bioscience, Inc., and System Biosciences, LLC.

Some of the recent developments in the miRNA Sequencing and Assay Market are:

  • In January 2022, research on Genome-Scale Study and Absolute Quantification of Circulating MicroRNA Biomarkers Using a MicroRNA Next-Generation-Sequencing Discovery Assay (miND) was conducted. For chronic and acute disorders as well as drug-induced harm, circulating levels of stem-cell microRNAs can be employed as diagnostic, disease severity, and prognostic indicators. As a result, the use of multivariate statistics to combine various microRNAs into marker signatures appears to be very potent in terms of tissues and disorder microRNA shed into the plasma.
  • In June 2020, the novel TraPR Small RNA Isolation Kit was announced by Lexogen, delivering the next sequencing firm. TraPR also known as Trans-Kingdom, Rapid, Affordable Purification of RISCs is a technology that allows for the cost-effective, accurate, and highly repeatable extraction of functional short RNAs (sRNAs) without the use of gels.

Similar recent developments related to companies in miRNA Sequencing and Assay Market are tracked by the team at Persistence Market Research, which are available in the full report.

Market Segments Covered in miRNA Sequencing and Assay Market Analysis

By Component

  • Products
    • Library Preparation Kits
    • Sequencing Consumables
    • Instruments
  • Services

By Technology

  • Sequencing by Synthesis
  • Seq. by Oligonucleotide Ligation and Detection (SOLiD)
  • Nanopore Seq.
  • Sanger Seq.
  • Single Molecule Real-time (SMRT) Seq.

By Workflow

  • Library Preparation
  • Sequencing
  • Data Analysis & Storage

By Application

  • Cancer
  • Polyglutamine Diseases
  • Autoimmune Disease
  • Schizophrenia
  • Other Applications

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

- Companies Covered in This Report -

  • Thermo Fisher Scientific
  • Illumina
  • QIAGEN
  • PerkinElmer
  • Abcam plc
  • New England Biolabs
  • Takara Bio Inc.
  • Lexogen GmbH
  • Norgen Biotek Corp
  • Maravai LifeSciences
  • HTG Molecular Diagnostics
  • Meridian Bioscience, Inc.
  • System Biosciences, LLC

- Frequently Asked Questions -

The global miRNA Sequencing and Assay Market is worth more than US$ 227.7 Mn at present.

The value of the miRNA Sequencing and Assay Market is projected to increase at a CAGR of around 18.1% during 2022 – 2032.

The value of the miRNA Sequencing and Assay Market increased at a CAGR of around 16.2% during 2017 – 2021.

The market for miRNA Sequencing and Assay Market in US is projected to expand at a CAGR of around 17.7% during 2022 – 2032.

Google translate